Edgewise Therapeutics, Inc. (EWTX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Edgewise Therapeutics, Inc. (EWTX) Earnings Overview
As of June 22, 2026, Edgewise Therapeutics, Inc. (EWTX) reported trailing twelve-month net income of -$176M, reflecting -12.4% year-over-year growth. The company earned $-1.64 per diluted share over the past four quarters.
Looking at the long-term picture, EWTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2019.
Edgewise Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), KYMR (-$315M net income, -794.4% margin), CMPS (-$179M net income), EWTX has comparable earnings metrics. Compare EWTX vs ACAD →
EWTX Earnings vs Peers
Earnings metrics vs comparable public companies
EWTX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$168M | -25.4% | -$191M | $-1.63 | - | - |
| 2024 | -$134M | -33.6% | -$159M | $-1.45 | - | - |
| 2023 | -$100M | -48.1% | -$114M | $-1.57 | - | - |
| 2022 | -$68M | -58.0% | -$72M | $-1.26 | - | - |
| 2021 | -$43M | -151.0% | -$43M | $-0.86 | - | - |
| 2020 | -$17M | -79.8% | -$17M | $-0.35 | - | - |
| 2019 | -$9M | - | -$10M | $-0.19 | - | - |
Download Data
Export EWTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EWTX — Frequently Asked Questions
Quick answers to the most common questions about buying EWTX stock.
What is EWTX earnings per share (EPS)?
EWTX trailing twelve-month (TTM) diluted EPS is $-1.64, reflecting -12.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Edgewise Therapeutics, Inc.'s net income?
Edgewise Therapeutics, Inc. (EWTX) trailing twelve-month net income is $-176M as of 2025. Earnings declined -12.4% year-over-year.
Is EWTX profitable?
EWTX is not currently profitable on a TTM basis, reporting a net loss of $-176M. Net margin is N/A. Investors should monitor for a return to profitability.
What is EWTX's earnings growth rate?
EWTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are EWTX's profit margins?
Edgewise Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -34.2%.
Is EWTX growing earnings?
EWTX earnings are declining — EPS fell -12.4% year-over-year. TTM net income dropped to $-176M. This contrasts with the 5-year CAGR of N/A.
What was EWTX's best earnings year?
Edgewise Therapeutics, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were EWTX's earnings last quarter?
EWTX's most recent reported quarter was Q1 2026. Net income was $-49M with diluted EPS of $-0.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.